MAPT and tauopathy: In line with global efforts to develop disease‐specific iPSC models and our longstanding interest in tauopathies, we used CRISPR/Cas9–mediated genome editing to generate iPSC lines carrying well‐characterized MAPT mutations, P301L or R406W, which are linked to FTD.59, 60, 61, 62